uMotif is a technology company.
uMotif has raised $35.0M across 3 funding rounds.
uMotif has raised $35.0M in total across 3 funding rounds.
uMotif has raised $35.0M in total across 3 funding rounds.
uMotif's investors include Albion VC.
uMotif is a London-based technology company founded in 2012 that builds a cloud-based, patient-centric eCOA/ePRO (electronic Clinical Outcome Assessment/electronic Patient-Reported Outcomes) and eConsent platform for capturing real-world evidence data in clinical trials and healthcare.[1][2][3] It serves pharmaceutical sponsors, clinical research organizations, sites, and patients by solving key challenges like low patient engagement, high dropouts, incomplete data, and legacy technology limitations through modern, configurable tools that boost compliance, retention, and data quality.[1][2][4] The platform includes features like daily self-tracking, medication reminders, cognitive games, symptom logging, wearable integration, eConsent management, and AI-driven assistants, with over 50% of revenues now from the USA and recognition as a major contender in Everest Group's 2025 eCOA PEAK Matrix.[1][2]
uMotif's growth momentum is strong, stemming from early NHS-funded projects (e.g., £571,107 for medicines management) to global scale, including large research initiatives with 18,000+ participants generating 9 million+ data points, and recent innovations like MotifAI for faster trials.[1][2][4]
uMotif was co-founded in 2012 by Bruce Hellman (CEO) and Ben James after they met two Parkinson's patients seeking digital tools to track symptoms, medications, and healthcare journeys for better self-management and clinician communication.[1][4] Hellman, emphasizing patient-centricity, drew from experiences in healthcare innovation to create a smartphone/web platform that evolved from self-management aids to a full eCOA/ePRO solution.[1][2]
The idea gained early traction through SBRI Healthcare funding for medication adherence tools, leading to NHS adoption that saved time, money, and paper while improving outcomes.[1] Pivotal moments included launching large-scale projects with 18,000 participants donating 9 million data points, prompting a shift to clinical research, and expanding globally with a team of industry experts in trials, operations, and patient engagement.[1][4]
uMotif stands out in the eCOA/ePRO market through these key strengths:
uMotif rides the wave of digital transformation in clinical trials, where patient-centric eCOA/ePRO platforms address rising demands for real-world evidence, decentralized trials, and regulatory pushes for diverse, high-quality patient data amid legacy system failures.[2][4] Timing is ideal as post-pandemic shifts accelerate remote monitoring, AI integration, and value-based care, with market forces like pharma's need for faster trials (reducing timelines via MotifAI) and NHS/global cost savings favoring scalable SaaS over hardware.[1][2]
It influences the ecosystem by setting standards for engagement—e.g., empowering patients in Parkinson's and beyond—driving better outcomes, research efficiency, and adoption in life sciences, while contributing thought leadership like eDiary guidelines.[1][2][4]
uMotif is poised for accelerated growth through AI enhancements, global expansion (building on 50%+ US revenue), and deeper integrations in decentralized/hybrid trials, potentially capturing more of the booming eCOA market projected to grow with rising trial complexity.[2] Trends like AI-driven personalization, wearable proliferation, and regulatory emphasis on patient voices will amplify its edge, evolving its influence from innovator to category leader in patient-empowered research.
This positions uMotif as a foundational player in modern clinical data capture, transforming patient experiences from reactive to proactive.[1][2][4]
uMotif has raised $35.0M across 3 funding rounds. Most recently, it raised $25.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $25.0M Series B | Albion VC | |
| Sep 1, 2020 | $7.0M Series A | Albion VC | |
| Jun 1, 2018 | $3.0M Venture Round | Albion VC |